CLINUVEL Pharmaceuticals has announced that its Board of Directors is considering a significant restructuring that would see the company transition from the Australian Securities Exchange to the Nasdaq Stock Market. The proposal involves a change to the company’s group holding structure, with current shareholders receiving equivalent shares in a new foreign holding company that would be listed on Nasdaq, effectively delisting from the ASX and Börse Frankfurt.
The strategic rationale reflects CLINUVEL’s operational reality. The company’s research activities are conducted in Singapore, while commercial and clinical operations span the United Kingdom, European Union, and United States. Critically, all of CLINUVEL’s revenues are currently generated in Europe and North America, with the company establishing its operational headquarters in the United States, effective from 1 January 2027. The majority of senior executives are already based outside Australia. Given this geographic distribution, a U.S. focused structure and Nasdaq listing would align the company’s domicile with its actual business operations and the largest global market for scientific innovation.
The transaction would be structured as a Scheme of Arrangement under Part 5.1 of the Corporations Act 2001. Current CLINUVEL shareholders would receive ordinary shares in the new holding company representing an equivalent proportionate economic interest to their existing holdings, subject to rounding of fractional entitlements. The new holding company would apply for listing on the Nasdaq Global Select Market.
A U.S. listing would potentially broaden CLINUVEL’s investor base and provide access to a larger, more specialized life sciences capital market better suited to biopharmaceutical companies. This could improve liquidity and valuation multiples over time. However, the transition introduces execution risk and regulatory uncertainty. The final Board decision has not yet been made, and the transaction remains contingent on finalisation of structure and documentation, followed by shareholder approval via scheme vote, Court approval, ASX approval, and other necessary regulatory clearances.
Shareholders do not need to take any action at this time and all existing security holdings remain unaffected during the evaluation phase. Further details regarding transaction structure, implementation timeline, and the treatment of existing listings will be provided as the Board progresses its consideration.
Investors should monitor upcoming announcements for the Board’s final decision, the formal scheme booklet with detailed terms and voting details, and the timeline for shareholder meetings and regulatory approvals. Successful completion of this restructuring would fundamentally change CLINUVEL’s listing jurisdiction and could have implications for tax treatment, dividend policies, and the regulatory environment in which the company operates. This announcement has been classified as price sensitive and flagged as material by the ASX.
View the full ASX announcement (PDF)
About Clinuvel Pharmaceuticals Limited (ASX: CUV)
Clinuvel Pharmaceuticals Limited is an Australian specialty pharmaceutical company headquartered in Melbourne that develops and commercializes treatments for genetic, metabolic, systemic, and life-threatening disorders. Its lead product, SCENESSE (afamelanotide 16mg), is approved for preventing phototoxicity in patients with erythropoietic protoporphyria and is available in Europe, the United States, Israel, and Australia. The company maintains a pipeline of additional therapies targeting neurological and degenerative disorders.
If you would like to discuss this announcement or how it might affect your portfolio, request a callback or call us on 1300 889 603.
